Advertisement
Advertisement
ALXO
ALX Oncology Holdings Inc. Common Stock
1.90
USDSponsored
+0.01
+0.53%
May 29, 15:59 UTC -4
Closed
After-Market
1.92
+0.02
+1.00%
ALXO Earnings Reports
Positive Surprise Ratio
ALXO beat 13 of 24 last estimates.
54%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.14
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-67.44%
ALX Oncology Holdings Inc. Common Stock earnings per share and revenue
On May 08, 2026, ALXO reported earnings of -0.14 USD per share (EPS) for Q1 26, beating the estimate of -0.19 USD, resulting in a 26.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +11.23% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were ALX Oncology Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ALX Oncology Holdings Inc. Common Stock reported EPS of -$0.14, beating estimates by 26.23%, and revenue of $0.00, 0% as expectations.
How did the market react to ALX Oncology Holdings Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 11.23%, changed from $1.87 before the earnings release to $2.08 the day after.
When is ALX Oncology Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for ALX Oncology Holdings Inc. Common Stock's next earnings report?
Based on 6
analysts, ALX Oncology Holdings Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement